Stoke Therapeutics, Inc. (STOK) — closed signal from October 12, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 10, 2026.
Predicted vs. what happened
What happened
Reached its target in 4 days.
The thesis — published October 12, 2025
Short-term traders are pushing the price up, and interest remains strong. Recent 2-3 year study results for zorevunersen showed steady gains in thinking and behavior for people with Dravet syndrome, suggesting the drug may change the course of the disease. Because smaller biotech stocks can swing a lot, consider buying on dips and use tight exit plans over the next 0-3 months.
Primary drivers
- New multi-year Dravet data (10-09, 10-10) shows steady patient improvement
- Price trend is rising and more buyers than usual are stepping in
- Optimistic mood can keep attracting interest after good news
- Buying in stages on down days helps handle sharp price swings
How it played out
STOK: target reached in 4 days
Lyra published STOK at $30.19 on 2025-10-12 with a short-term thesis for 25% growth. The thesis pointed to multi-year zorevunersen data in Dravet syndrome, a rising price trend, stronger buyer interest, and a view that optimistic mood after good news could keep attracting interest.
Inside the window, STOK reached the target. The peak was $38.69 on 2025-10-16, with a 28.2% gain, and the target was reached in 4 days. By 2026-01-10, the stock ended at $32.85. The published thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.